WILEX is a biopharmaceutical company based in Munich and listed on the Frankfurt Stock Exchange in the Regulated Market / Prime Standard. The Company was founded in 1997 by a team of physicians and oncologists from the Technical University of Munich.
Focused on oncology, the Company’s portfolio includes diagnostic and therapeutic product candidates for the specific detection and targeted treatment of various types of cancer based on antibodies and small molecules. Our aim is out-licensing these clinical projects. The Wilex subsidiary Heidelberg Pharma GmbH in Ladenburg, Germany, offers preclinical contract research services and an antibody drug conjugate (ADC) technology platform.
The business model of WILEX thus comprises research, technology platform, customer specific research and development collaboration.
Company Growth (employees)